Question: Which of the following is NOT routinely recommended to decrease the risk of cardiovascular disease (CVD) in patients with rheumatoid arthritis?
24% of
Medical Professionals
Chose A
5% of
Medical Professionals
Chose B
37% of
Medical Professionals
Chose C
35% of
Medical Professionals
Chose D
Answer: C. A randomized trial of atorvastatin for prevention of CVD in patients with RA was stopped early because of lower than expected number of events, but did not show a statistically significant decrease in CV events. We use the same guidelines for initiating statin therapy in a patient with RA as in the general population. Usual measures to modify CV risk and minimizing duration of glucocorticoid therapy can decrease risk in RA. Observational data also suggest that strict control of inflammation in RA with use of therapy to decrease synovial inflammation may reduce the development of progression of cardiovascular disease.
Yes, start my risk-free subscription today!
As you can see from the results above, it's a challenge to always identify the correct diagnosis. That's why UpToDate offers 1, 2, and 3-year subscriptions and group subscription options — so you can find clinical answers quickly.
Have you had the opportunity to read a sample UpToDate topic? Now is your chance! Click here to view sample topics in your specialty and 24 others and see how UpToDate can help you find accurate answers to your clinical questions— quickly and easily.
Don't miss the UpToDate Clinical challenge questions each week on Facebook — put your clinical knowledge to the test! You can also follow UpToDate on social media via Twitter, YouTube, and LinkedIn.